Meeting NewsVideo

VIDEO: Loading dose of secukinumab affects outcomes in PsA

SAN DIEGO – Secukinumab may be an effective treatment for patients with psoriatic arthritis, according to findings presented at the American College of Rheumatology Annual Meeting.

Eric M. Ruderman, MD, professor of medicine at Northwestern University’s Feinberg School of Medicine, describes the trial design and the results. The study included one arm that was not treated with a loading dose and two arms that were.

Patients who did not receive a loading dose “didn’t seem to do as well” as patients who did, which suggests that treatment with a loading dose “is the appropriate way to use this medication in clinical practice,” according to Ruderman.

SAN DIEGO – Secukinumab may be an effective treatment for patients with psoriatic arthritis, according to findings presented at the American College of Rheumatology Annual Meeting.

Eric M. Ruderman, MD, professor of medicine at Northwestern University’s Feinberg School of Medicine, describes the trial design and the results. The study included one arm that was not treated with a loading dose and two arms that were.

Patients who did not receive a loading dose “didn’t seem to do as well” as patients who did, which suggests that treatment with a loading dose “is the appropriate way to use this medication in clinical practice,” according to Ruderman.

    See more from Discoveries from ACR: Spondyloarthropathies